Cargando…

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes

Recent data have indicated the emerging role of glomerular autophagy in diabetic kidney disease. We aimed to assess the effect of the SGLT2 inhibitor empagliflozin, the DPP4 inhibitor linagliptin, and their combination, on glomerular autophagy in a model of type 2 diabetes. Eight-week-old male db/db...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korbut, Anton I., Taskaeva, Iuliia S., Bgatova, Nataliya P., Muraleva, Natalia A., Orlov, Nikolai B., Dashkin, Maksim V., Khotskina, Anna S., Zavyalov, Evgenii L., Konenkov, Vladimir I., Klein, Thomas, Klimontov, Vadim V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215949/ https://www.ncbi.nlm.nih.gov/pubmed/32340263 http://dx.doi.org/10.3390/ijms21082987

Ejemplares similares

Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice
por: Klimontov, Vadim V, et al.
Publicado: (2020)

Linagliptin alleviates fatty liver disease in diabetic db/db mice
por: Michurina, Svetlana V, et al.
Publicado: (2016)

Multiplex Bead Array Assay of a Panel of Circulating Cytokines and Growth Factors in Patients with Albuminuric and Non-Albuminuric Diabetic Kidney Disease
por: Klimontov, Vadim V., et al.
Publicado: (2020)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice
por: Fushimi, Yoshiro, et al.
Publicado: (2021)

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
por: Gallo, Linda A., et al.
Publicado: (2016)

Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
por: Gallo, Linda A., et al.
Publicado: (2016)

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
por: Jojima, Teruo, et al.
Publicado: (2016)

Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice
por: Pham, Trong Kha, et al.
Publicado: (2023)

Cardioprotective effects of short-term empagliflozin treatment in db/db mice
por: Radlinger, Bernhard, et al.
Publicado: (2020)

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
por: Bamba, Ryo, et al.
Publicado: (2021)

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
por: Tu, Yimin, et al.
Publicado: (2022)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8
por: Takiyama, Yumi, et al.
Publicado: (2018)

Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
por: Hata, Shinnosuke, et al.
Publicado: (2022)

Trehalose Activates Hepatic and Myocardial Autophagy and Has Anti-Inflammatory Effects in db/db Diabetic Mice
por: Korolenko, Tatiana A., et al.
Publicado: (2022)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Treatment with Autophagy Inducer Trehalose Alleviates Memory and Behavioral Impairments and Neuroinflammatory Brain Processes in db/db Mice
por: Korolenko, Tatiana A., et al.
Publicado: (2021)

Characterization of the Aquaporin-9 Inhibitor RG100204 In Vitro and in db/db Mice
por: Florio, Marilina, et al.
Publicado: (2022)

Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse
por: Hayden, Melvin R., et al.
Publicado: (2019)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022)

The PKD Inhibitor CID755673 Enhances Cardiac Function in Diabetic db/db Mice
por: Venardos, Kylie, et al.
Publicado: (2015)

ODP037 Effects of DHCR24 Inhibitor on Excessive Adrenal Steroidogenesis in db/db mouse
por: Kamigaki, Risa, et al.
Publicado: (2022)

Study of Lithium Biodistribution and Nephrotoxicity in Skin Melanoma Mice Model: The First Step towards Implementing Lithium Neutron Capture Therapy
por: Taskaeva, Iuliia, et al.
Publicado: (2023)

Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
por: Woo, V.
Publicado: (2015)

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
por: Darsalia, Vladimer, et al.
Publicado: (2013)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Cosmos DB for MongoDB developers: migrating to Azure Cosmos DB and using the MongoDB API
por: Sharma, Manish
Publicado: (2018)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015)

Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice
por: Kim, Jung Eun, et al.
Publicado: (2013)

ATP-citrate lyase inhibitor improves ectopic lipid accumulation in the kidney in a db/db mouse model
por: Zhan, Zishun, et al.
Publicado: (2022)

DPP‐4 Inhibitor Linagliptin Attenuates Aβ‐induced Cytotoxicity through Activation of AMPK in Neuronal Cells
por: Kornelius, Edy, et al.
Publicado: (2015)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice
por: Sun, Jing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u3hfr6nm73tp1pbbm8fdqcn8h4